## Randomized Trial of Verubecestat for Mild-to-Moderate

New England Journal of Medicine 378, 1691-1703 DOI: 10.1056/nejmoa1706441

Citation Report

#	ARTICLE	IF	Citations
2	Somatic APP gene recombination in Alzheimer's disease and normal neurons. Nature, 2018, 563, 639-645.	27.8	179
3	Effects of a Dehydroevodiamine-Derivative on Synaptic Destabilization and Memory Impairment in the 5xFAD, Alzheimer's Disease Mouse Model. Frontiers in Behavioral Neuroscience, 2018, 12, 273.	2.0	22
4	Pathological Increases in Neuronal Hyperactivity in Selective Cholinergic and Noradrenergic Pathways May Limit the Efficacy of Amyloid-β-Based Interventions in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2018, 2, 165-167.	2.2	3
5	Pathogenic Feed-Forward Mechanisms in Alzheimer's and Parkinson's Disease Converge on GSK-3. Brain Plasticity, 2018, 4, 151-167.	3.5	19
6	Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor. ACS Symposium Series, 2018, , 91-114.	0.5	0
7	Alzheimer's disease: The right drug, the right time. Science, 2018, 362, 1250-1251.	12.6	114
8	Cerebrospinal fluid neurogranin/βâ€site APPâ€cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 617-627.	3.7	24
9	Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. ACS Symposium Series, 2018, , 53-89.	0.5	0
10	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. Neurotherapeutics, 2018, 15, 1032-1035.	4.4	8
11	Alzheimer's disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	4.4	59
12	Alzheimer's disease (AD) therapeutics – 2: Beyond amyloid – Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	4.4	24
13	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	2.8	66
14	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional AÎ <sup>2</sup> deposition rate and plaque burden at treatment initiation. Theranostics, 2018, 8, 4957-4968.	10.0	22
15	Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain1. Journal of Alzheimer's Disease Reports, 2018, 2, 169-179.	2.2	5
16	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	7.7	151
17	A promising, novel, and unique <scp>BACE</scp> 1 inhibitor emerges in the quest to prevent Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	6.9	28
18	Insulin Resistance in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 830.	2.8	147
19	The <scp>BACE</scp> â€1 inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	6.9	112

#	Article	IF	CITATIONS
20	Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Science Translational Medicine, 2018, 10, .	12.4	66
21	Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. Biological Psychiatry, 2018, 84, 478-487.	1.3	41
22	Sex differences in Alzheimer disease — the gateway to precision medicine. Nature Reviews Neurology, 2018, 14, 457-469.	10.1	573
23	BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines. Frontiers in Aging Neuroscience, 2018, 10, 229.	3.4	27
24	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. Alzheimer's Research and Therapy, 2018, 10, 85.	6.2	69
25	Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy. Journal of Neurology, 2019, 266, 1566-1577.	3.6	23
26	Effect and Safety of Huannao Yicong Formula (è¿~è"ʻç›Šèªæ−1) in Patients with Mild-to-Moderate Alzheimer's A Randomized, Double-Blinded, Donepezil-Controlled Trial. Chinese Journal of Integrative Medicine, 2019, 25, 574-581.	Disease: 1.6	16
27	Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity. Trends in Pharmacological Sciences, 2019, 40, 655-668.	8.7	21
28	EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	2.7	18
29	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 68.	6.2	44
30	Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its halfâ€life. Alzheimer's and Dementia, 2019, 15, 1183-1194.	0.8	17
31	Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine, 2019, 286, 398-437.	6.0	102
32	Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293.	3.7	546
33	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease. Scientific Reports, 2019, 9, 9870.	3.3	35
34	Sleep and β-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments. Frontiers in Pharmacology, 2019, 10, 695.	3.5	85
35	Early Al̂² reduction prevents progression of cerebral amyloid angiopathy. Annals of Neurology, 2019, 86, 561-571.	5.3	18
36	Kihito, a Traditional Japanese Kampo Medicine, Improves Cognitive Function in Alzheimer's Disease Patients. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-7.	1.2	18
37	Canine Cognitive Dysfunction and Alzheimer's Disease – Two Facets of the Same Disease?. Frontiers in Neuroscience, 2019, 13, 604.	2.8	56

#	Article	IF	CITATIONS
38	Brain AÎ <sup>2</sup> load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285.	0.8	25
39	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. PLoS ONE, 2019, 14, e0224030.	2.5	26
40	Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. Journal of Alzheimer's Disease, 2019, 72, 443-454.	2.6	25
41	Applications of Quantitative Systems Pharmacology in Modelâ€Informed Drug Discovery: Perspective on Impact and Opportunities. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 777-791.	2.5	45
42	Investigational BACE inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2019, 28, 967-975.	4.1	94
43	Tau deletion reduces plaqueâ€associated <scp>BACE</scp> 1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease. EMBO Journal, 2019, 38, e102345.	7.8	24
44	Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America. Pharmaceutical Medicine, 2019, 33, 511-518.	1.9	2
45	Randomized controlled trial of TDCS on cognition in 201 seniors with mild neurocognitive disorder. Annals of Clinical and Translational Neurology, 2019, 6, 1938-1948.	3.7	43
46	Trifluoromethyl Dihydrothiazineâ€Based βâ€Secretase (BACE1) Inhibitors with Robust Central βâ€Amyloid Reduction and Minimal Covalent Binding Burden. ChemMedChem, 2019, 14, 1894-1910.	3.2	8
47	Emerging Approaches to Investigate the Influence of Transition Metals in the Proteinopathies. Cells, 2019, 8, 1231.	4.1	19
48	History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduction and Targeted Therapy, 2019, 4, 29.	17.1	370
49	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects. Journal of Alzheimer's Disease, 2019, 71, 581-595.	2.6	16
51	Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2019, 20, 2095-2099.	1.8	13
52	Development of new treatments for Alzheimer's disease based on the modulation of translocator protein (TSPO). Ageing Research Reviews, 2019, 54, 100943.	10.9	10
53	Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2019, 82, 264-278.	4.1	37
54	Combinatorial Treatment Using Umbilical Cord Perivascular Cells and AÎ <sup>2</sup> Clearance Rescues Vascular Function Following Transient Hypertension in a Rat Model of Alzheimer Disease. Hypertension, 2019, 74, 1041-1051.	2.7	11
55	Refining the understanding of typical Alzheimer disease. Nature Reviews Neurology, 2019, 15, 623-624.	10.1	3
56	Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: A 52â€week randomized controlled trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 441-449.	3.7	14

ARTICLE IF CITATIONS # Do anti-amyloid-Î<sup>2</sup> drugs affect neuropsychiatric status in Alzheimer's disease patients?. Ageing Research 10.9 24 57 Reviews, 2019, 55, 100948. Spore powder of Ganoderma lucidum for Alzheimer's disease. Medicine (United States), 2019, 98, e14382. 1.0 9 59 Risk Factors for Alzheimer's Disease: Focus on Stress. Frontiers in Pharmacology, 2019, 10, 976. 3.5 20 Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339. 1,675 Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. European Journal of Medicinal 61 5.5 46 Chemistry, 2019, 183, 111707. New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities. Organic Process Research and Development, 2019, 23, 2470-2481. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, S145-S176. 63 2.6 26 Discovery of an Extremely Potent Thiazine-Based Î<sup>2</sup>-Secretase Inhibitor with Reduced Cardiovascular 64 6.4 and Liver Toxicity at a Low Projected Human Dose. Journal of Medicinal Chemistry, 2019, 62, 9331-9337. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. 65 2.6 336 Journal of Alzheimer's Disease, 2019, 67, 779-794. Design, synthesis, and biological evaluation of 4â€aminopyrimidine or 4,6â€diaminopyrimidine derivatives 3.2 as beta amyloid cleaving enzymeâ€1 inhibitors. Chemical Biology and Drug Design, 2019, 93, 926-933. Lack of Î<sup>2</sup>-amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo. Brain Structure and Function, 67 2.39 2019, 224, 1279-1290. Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 2: Spheroids, Organoids, and Disease 68 Modeling. SLAS Technology, 2019, 24, 18-27. A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal 69 5.4 17 of Pharmacology, 2019, 176, 3636-3648. The βâ€secretase (BACE) inhibitor NBâ€360 in preclinical models: From amyloidâ€Î² reduction to downstream 5.4 diseaseâ€relevant effects. British Journal of Pharmacology, 2019, 176, 3435-3446. Sex differences in Alzheimer's disease: Understanding the molecular impact. Brain Research, 2019, 1719, 71 2.2 53 194-207. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. Expert Review of Neurotherapeutics, 2019, 19, 599-602. Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's 73 4.4 49 disease. Neurobiology of Disease, 2019, 130, 104511. Plant-based vaccines for Alzheimer's disease. Proceedings of the Japan Academy Series B: Physical and 74 3.8 Biological Sciences, 2019, 95, 290-294.

#	Article	IF	CITATIONS
75	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	3.7	80
76	Safety, Tolerability, and Pharmacokinetics of the βâ€Site Amyloid Precursor Proteinâ€Cleaving Enzyme 1 Inhibitor Verubecestat ( <scp>MK</scp> â€8931) in Healthy Elderly Male and Female Subjects. Clinical and Translational Science, 2019, 12, 545-555.	3.1	14
77	Neuroprotection in Alzheimer Disease. Springer Protocols, 2019, , 465-585.	0.3	1
78	β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?. Lancet Neurology, The, 2019, 18, 624-626.	10.2	17
79	Combining hippocampal volume metrics to better understand Alzheimer's disease progression in at-risk individuals. Scientific Reports, 2019, 9, 7499.	3.3	16
80	Identification of Temporal Characteristic Networks of Peripheral Blood Changes in Alzheimer's Disease Based on Weighted Gene Co-expression Network Analysis. Frontiers in Aging Neuroscience, 2019, 11, 83.	3.4	25
81	A metabolic perspective of late onset Alzheimer's disease. Pharmacological Research, 2019, 145, 104255.	7.1	19
82	ADVANCING ALZHEIMER'S DISEASE TREATMENT: LESSONS FROM CTAD 2018. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-6.	2.7	6
83	COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER'S DISEASE – THE NEXT STEP. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	2.7	0
84	Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 46.	6.2	83
85	Bispecific Antibody Fragment Targeting APP and Inducing α-Site Cleavage Restores Neuronal Health in an Alzheimer's Mouse Model. Molecular Neurobiology, 2019, 56, 7420-7432.	4.0	9
86	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. Neurobiology of Disease, 2019, 127, 605-615.	4.4	79
87	Disease Modification in Alzheimer's Disease: Current Thinking. Therapeutic Innovation and Regulatory Science, 2019, , 216847901984189.	1.6	1
88	Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. Journal of Medicinal Chemistry, 2019, 62, 5080-5095.	6.4	29
89	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron, 2019, 101, 1003-1015.	8.1	29
90	A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. CNS Drugs, 2019, 33, 251-263.	5.9	115
91	New flavonoid – <i>N</i> , <i>N</i> -dibenzyl( <i>N</i> -methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	5.2	27
92	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. Journal of the American Geriatrics Society, 2019, 67, 845-847.	2.6	4

#	Article	IF	CITATIONS
93	Lowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures. New England Journal of Medicine, 2019, 380, 1476-1478.	27.0	56
94	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. New England Journal of Medicine, 2019, 380, 1408-1420.	27.0	397
95	Carotid artery wave intensity in mid- to late-life predicts cognitive decline: the Whitehall II study. European Heart Journal, 2019, 40, 2300-2309.	2.2	57
96	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	1.3	18
97	Current and Future Treatments in Alzheimer's Disease. Seminars in Neurology, 2019, 39, 227-240.	1.4	161
98	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. International Journal of Molecular Sciences, 2019, 20, 901.	4.1	81
99	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated Aβ42 Species Aβ5–42. ACS Chemical Neuroscience, 2019, 10, 2374-2384.	3.5	16
100	Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?. Future Medicinal Chemistry, 2019, 11, 261-263.	2.3	13
101	Early Diagnosis of Alzheimer's Disease. , 2019, , 7-12.		0
102	Present Algorithms and Future Treatments for Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 67, 1157-1171.	2.6	76
103	Dynamic Docking of a Medium-Sized Molecule to Its Receptor by Multicanonical MD Simulations. Journal of Physical Chemistry B, 2019, 123, 2479-2490.	2.6	22
104	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. Journal of Alzheimer's Disease, 2019, 68, 537-550.	2.6	11
105	The Role of Biomarkers in Alzheimer's Disease Drug Development. Advances in Experimental Medicine and Biology, 2019, 1118, 29-61.	1.6	84
106	Curcumin Alleviates β Amyloid-Induced Neurotoxicity in HT22 CellsÂvia Upregulating SOD2. Journal of Molecular Neuroscience, 2019, 67, 540-549.	2.3	17
107	Arousal and the Alzheimer disease. , 2019, , 131-141.		1
108	Diagnosis and Treatment of Alzheimer's Disease in Elderly and Senile Age. Advances in Gerontology, 2019, 9, 439-446.	0.4	0
109	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Scientific Reports, 2019, 9, 19877.	3.3	25
110	Preventing Cognitive Decline and Dementia. , 2019, , 291-306.		2

#	Article	IF	CITATIONS
111	Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	6.2	131
112	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	5.9	33
113	A critical appraisal of amyloid-β-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	10.1	666
114	Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?. Immunotherapy, 2019, 11, 3-6.	2.0	50
115	New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 761-777.	2.2	57
116	Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 922-930.	3.5	6
117	New approaches for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 125-133.	2.2	111
118	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	5.4	71
119	Bad news and good news in AD, and how to reconcile them. Nature Reviews Neurology, 2019, 15, 61-62.	10.1	35
120	Amyloidâ€Î² immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	5.3	126
121	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. Journal of Experimental Medicine, 2019, 216, 279-293.	8.5	55
122	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	2.8	45
123	Pathological Changes of Tau Related to Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 931-944.	3.5	54
124	Current viral-mediated gene transfer research for treatment of Alzheimer's disease. Biotechnology and Genetic Engineering Reviews, 2019, 35, 26-45.	6.2	14
125	Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease. Journal of Neuroimmunology, 2019, 326, 62-74.	2.3	170
126	Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system. Pharmacological Research, 2020, 154, 104230.	7.1	37
127	Discovery of AM-6494: A Potent and Orally Efficacious Î <sup>2</sup> -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. Journal of Medicinal Chemistry, 2020, 63, 2263-2281.	6.4	25
128	Quantification and pharmacokinetic property of verubecestat an BACE1 inhibitor in rat plasma. Biomedical Chromatography, 2020, 34, e4715.	1.7	2

#	Article	IF	CITATIONS
129	Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer's disease. International Journal of Biological Macromolecules, 2020, 142, 265-276.	7.5	41
130	Reduction of blood glucose by plant extracts and their use in the treatment of diabetes mellitus; discrepancies in effectiveness between animal and human studies. Journal of Ethnopharmacology, 2020, 247, 112264.	4.1	34
131	A combinational treatment of carotenoids decreases AÎ <sup>2</sup> secretion in human neurons via Î <sup>2</sup> -secretase inhibition. Neuroscience Research, 2020, 158, 47-55.	1.9	7
132	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. Medicinal Research Reviews, 2020, 40, 339-384.	10.5	177
133	Aspirin and its pleiotropic application. European Journal of Pharmacology, 2020, 866, 172762.	3.5	64
134	A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer's Disease. Journal of Immunology, 2020, 204, 243-250.	0.8	26
135	Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 38-53.	4.3	64
136	δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities. Translational Neurodegeneration, 2020, 9, 1.	8.0	60
137	Endosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology. Ageing Research Reviews, 2020, 58, 101006.	10.9	29
138	Mouse brain proteomics establishes MDGA1 and CACHD1 as in vivo substrates of the Alzheimer protease BACE1. FASEB Journal, 2020, 34, 2465-2482.	0.5	16
139	Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer's disease. Neurobiology of Aging, 2020, 86, 81-91.	3.1	18
140	Sequential parallel comparison design with two coprimary endpoints. Pharmaceutical Statistics, 2020, 19, 243-254.	1.3	2
141	Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease. JAMA Neurology, 2020, 77, 199.	9.0	123
142	Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. Drug Discovery Today, 2020, 25, 2110-2129.	6.4	12
143	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 3499-3509.	3.5	7
144	Anti-Al̂² agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1316-1324.	1.9	24
145	Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554.	3.5	300
146	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β. Journal of Alzheimer's Disease, 2020, 77, 1639-1653.	2.6	8

#	Article	IF	CITATIONS
147	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1483-1492.	0.8	46
148	Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and CSK-3 dual inhibitors for Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 207, 112751.	5.5	15
149	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. Expert Opinion on Investigational Drugs, 2020, 29, 919-933.	4.1	22
150	Alzheimer's disease drug development pipeline: 2020. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12050.	3.7	353
151	<i>Gga3</i> deletion and a <i>GGA3</i> rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings. Science Translational Medicine, 2020, 12, .	12.4	11
152	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 8673.	4.1	8
153	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain, 2020, 143, 3816-3826.	7.6	41
155	Neuronal deficiency of p38αâ€MAPK ameliorates symptoms and pathology of APP or Tauâ€ŧransgenic Alzheimer's mouse models. FASEB Journal, 2020, 34, 9628-9649.	0.5	19
156	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	13.7	4,658
157	An update on potential links between type 2 diabetes mellitus and Alzheimer's disease. Molecular Biology Reports, 2020, 47, 6347-6356.	2.3	28
158	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimer's and Dementia, 2020, 16, 1412-1425.	0.8	82
159	<scp>AP</scp> â€⊋ reduces amyloidogenesis by promoting <scp>BACE</scp> 1 trafficking and degradation in neurons. EMBO Reports, 2020, 21, e47954.	4.5	36
160	Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2020, 13, 137.	2.9	73
161	Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease. JAMA Network Open, 2020, 3, e2010372.	5.9	34
162	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of	10.8	44
	BACE1. Molecular Neurodegeneration, 2020, 15, 53.		
163	BACE1. Molecular Neurodegeneration, 2020, 15, 53. Current Biomarkers for Alzheimer's Disease: From CSF to Blood. Journal of Personalized Medicine, 2020, 10, 85.	2.5	42
163 164	BACE1. Molecular Neurodegeneration, 2020, 15, 53.   Current Biomarkers for Alzheimer's Disease: From CSF to Blood. Journal of Personalized Medicine, 2020, 10, 85.   Revisiting the Amyloid Cascade Hypothesis: From Anti-Âβ Therapeutics to Auspicious New Ways for Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	2.5 4.1	42 79

#	Article	IF	CITATIONS
166	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 583884.	3.4	14
167	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 9318.	4.1	54
168	Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimer's Disease. Frontiers in Genetics, 2020, 11, 390.	2.3	14
169	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer's Research and Therapy, 2020, 12, 58.	6.2	56
170	The Role of P2X7 Receptor in Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2020, 13, 94.	2.9	44
171	Alzheimer's Disease "Non-amyloidogenic―p3 Peptide Revisited: A Case for Amyloid-α. ACS Chemical Neuroscience, 2020, 11, 1539-1544.	3.5	23
172	Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease. Journal of the Neurological Sciences, 2020, 416, 116974.	0.6	48
173	Quantitative Analysis of 7 Compounds in <i>Diospyros lotus</i> Leaf Extract and Its Biological Effects on Neuroprotection and Antineuroinflammation. Natural Product Communications, 2020, 15, 1934578X2092485.	0.5	2
174	Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1. Journal of Alzheimer's Disease, 2020, 74, 43-53.	2.6	14
175	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells. Neurochemical Research, 2020, 45, 2113-2127.	3.3	2
176	Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease. Nature Communications, 2020, 11, 1377.	12.8	88
177	Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy. Frontiers in Pharmacology, 2020, 11, 248.	3.5	12
178	Discovery of small molecules for the treatment of Alzheimer's disease. , 2020, , 289-322.		1
179	Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology, 2020, 94, e1512-e1524.	1.1	53
180	Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls. ACS Pharmacology and Translational Science, 2020, 3, 472-488.	4.9	21
181	Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine, 2020, 9, 1919.	2.4	4
182	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
183	New BACE1 Chimeric Peptide InhibitorsÂSelectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models. Journal of Alzheimer's Disease, 2020, 76, 1317-1337.	2.6	6

#	Article	IF	CITATIONS
185	The Shaky Six and the "Second Reality― , 2020, , 1-10.		0
186	Pieces of a Puzzle?. , 2020, , 11-24.		0
187	Disease "Redefinition― A Tough Pill to Swallow. , 2020, , 25-32.		0
188	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
189	Protein Paradox. , 2020, , 41-56.		0
190	The Fault in Our Models. , 2020, , 57-70.		0
191	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
192	Lessons from Oncology. , 2020, , 81-86.		0
193	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
194	Our Living Dissonance. , 2020, , 105-110.		0
195	The Scientific and Lay Narratives. , 2020, , 111-124.		0
196	Challenges Viewed from Afar. , 2020, , 125-132.		0
197	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
198	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
199	Note Added at Press Time – Reviving LOF. , 2020, , 150-150.		0
202	Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2020, 35, 153331751989980.	1.9	9
203	Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	3.3	17
204	Pathogenic Aβ generation in familial Alzheimer's disease: novel mechanistic insights and therapeutic implications. Current Opinion in Neurobiology, 2020, 61, 73-81.	4.2	22

#	Article	IF	CITATIONS
205	Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. PLoS ONE, 2020, 15, e0228064.	2.5	9
206	Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice. European Journal of Neurology, 2020, 27, 928-943.	3.3	81
207	Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity. Brain Communications, 2020, 2, fcz046.	3.3	53
208	Disease Modification in Alzheimer's Disease: Current Thinking. Therapeutic Innovation and Regulatory Science, 2020, 54, 396-403.	1.6	12
209	New Insights Into the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1312.	2.4	194
210	Clarifying the Relationship Between Benzodiazepines and Dementia. Journal of the American Medical Directors Association, 2020, 21, 143-145.	2.5	6
211	Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. Translational Psychiatry, 2020, 10, 125.	4.8	48
212	Fish oil protects the blood–brain barrier integrity in a mouse model of Alzheimer's disease. Chinese Medicine, 2020, 15, 29.	4.0	14
213	Pharmaceutical applications of organofluorine compounds. , 2020, , 133-214.		0
214	Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nature Reviews Drug Discovery, 2020, 19, 447-462.	46.4	73
215	What works and what does not work in Alzheimer's disease? From interventions on risk factors to antiâ€amyloid trials. Journal of Neurochemistry, 2020, 155, 120-136.	3.9	26
216	Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 103.	3.4	79
217	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 112-125.	1.4	40
218	Passive antiamyloid immunotherapy for Alzheimer's disease. Current Opinion in Psychiatry, 2020, 33, 284-291.	6.3	40
219	Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy. International Journal of Alzheimer's Disease, 2020, 2020, 1-13.	2.0	62
220	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
221	Hebbian and Homeostatic Synaptic Plasticity—Do Alterations of One Reflect Enhancement of the Other?. Frontiers in Cellular Neuroscience, 2020, 14, 50.	3.7	27
222	Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. Frontiers in Pharmacology, 2020, 11, 261.	3.5	48

	Сітаті	on Report	
#	Article	IF	CITATIONS
223	The β-Secretase BACE1 in Alzheimer's Disease. Biological Psychiatry, 2021, 89, 745-756.	1.3	336
224	Physical exercise protocols in animal models of Alzheimer's disease: a systematic review. Metabolic Brain Disease, 2021, 36, 85-95.	2.9	26
225	Alzheimer Disease Pathogenesis: The Role of Autoimmunity. journal of applied laboratory medicine, The, 2021, 6, 756-764.	1.3	19
226	Clinical trials of promising apoptosis modulating drugs. , 2021, , 329-391.		1
227	β-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	10.9	27
228	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. Neuron, 2021, 109, 257-272.e14.	8.1	108
229	Protection against Alzheimer's disease by luteolin: Role of brain glucose regulation, antiâ€inflammatory activity, and the gut microbiotaâ€liverâ€brain axis. BioFactors, 2021, 47, 218-231.	5.4	69
230	Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. Annual Review of Medicine, 2021, 72, 15-28.	12.2	22
231	Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-6.	2.7	8
232	Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders. Neural Regeneration Research, 2021, 16, 1901.	3.0	23
233	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
234	Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 inÂvivo. Journal of Biological Chemistry, 2021, 296, 100372.	3.4	13
235	OUP accepted manuscript. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	3.0	0
236	Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12123.	3.7	9
237	Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. Journal of Alzheimer's Disease, 2021, 79, 275-287.	2.6	7
238	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. Neuroscientist, 2022, 28, 254-270.	3.5	9
239	Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. International Journal of Molecular Sciences, 2021, 22, 2360.	4.1	26
241	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 1176	576. 4.2	20

ARTICLE IF CITATIONS # Identification of aplysinopsin as a blood-brain barrier permeable scaffold for anti-cholinesterase and 242 4.1 12 anti-BACE-1 activity. Bioorganic Chemistry, 2021, 107, 104568. Natural Products Targeting Amyloid Beta in Alzheimer's Disease. International Journal of Molecular 243 4.1 Sciences, 2021, 22, 2341 Patient-derived iPSCs, a reliable <i>in vitro</i> model for the investigation of Alzheimer's disease. 244 2.9 5 Reviews in the Neurosciences, 2021, 32, 379-402. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based Î<sup>2</sup>-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. Journal of Medicinal Chemistry, 2021, 64, 245 6.4 1873-1888. New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease. Cerebral Cortex, 246 2.9 4 2021, 31, 3363-3373. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. JAMA Neurology, 2021, 78, 293. A Pathophysiological and Pharmacological review on Alzheimer's disease: A Current Need. Biomedical 248 0.5 1 and Pharmacology Journal, 2021, 14, 75-80. Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective Î<sup>2</sup>-Secretase (BACE1) Inhibitors over BACE2. Journal of Medicinal Chemistry, 2021, 240 6.4 64, 3075-3085. The use of the cellular thermal shift assay for the detection of intracellular beta-site amyloid 250 2.3 3 precursor protein cleaving enzyme-1 ligand binding. Molecular Biology Reports, 2021, 48, 2957-2962. The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. International 4.1 Journal of Molecular Sciences, 2021, 22, 3136. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study. Journal of Alzheimer's 252 7 2.6 Disease, 2021, 80, 673-681. Accelerated longâ€term forgetting is a BACE1 inhibitorâ€reversible incipient cognitive phenotype in 2.3 Alzheimer's disease model mice. Neuropsychopharmacology Reports, 2021, 41, 255-259. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. Neuroscientist, 2022, 28, 254 3.5 8 507-519. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571. Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimer's Disease. Cells, 256 4.1 27 2021, 10, 649. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology, 2021, 96, 944-954. 14 Preclinical validation of a potent Î<sup>3</sup>-secretase modulator for Alzheimer's disease prevention. Journal of 258 8.5 39 Experimental Medicine, 2021, 218, . Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD 34 mouse models. Molecular Neurodegeneration, 2021, 16, 14.

		CITATION REPORT		
#	Article		IF	Citations
260	Recent advances in pre-clinical diagnosis of Alzheimer's disease. Metabolic Brain Dise	ase, 2021, , 1.	2.9	3
261	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	central AÎ <sup>2</sup>	5.5	7
262	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Neurotherapeutics, 2021, 18, 686-708.		4.4	19
263	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary preve longitudinal amyloid PET imaging. Alzheimer's Research and Therapy, 2021, 13, 82.	ntion trials using	6.2	14
264	Alzheimer's disease and its treatment by different approaches: A review. European Jou Chemistry, 2021, 216, 113320.	ırnal of Medicinal	5.5	199
265	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheir Dementia. Journal of Alzheimer's Disease Reports, 2021, 5, 321-336.	ner's Disease	2.2	17
266	Shared Genetic Background Between Cerebrospinal Fluid Biomarkers and Risk for Alzhein A Two-Sample Mendelian Randomization Study. Journal of Alzheimer's Disease, 2021, 80,	ıer's Disease: 1197-1207.	2.6	3
267	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Applicat Alzheimer's Disease, 2021, 81, 19-32.	tion. Journal of	2.6	3
268	Systematic in silico analysis of clinically tested drugs for reducing amyloidâ€beta plaque a in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1487-1498.	accumulation	0.8	22
269	Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer's Disease Pathology Cognitive Deficits. Biomedicines, 2021, 9, 594.	and Improve	3.2	55
270	Effect of antiamyloid-β drugs on Alzheimer's disease: study protocol for a systematic meta-analysis. BMJ Open, 2021, 11, e048453.	review and	1.9	0
271	Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of Neurodegenerative on Network Pharmacology. Neurochemical Research, 2021, 46, 1881-1894.	Diseases Based	3.3	10
272	Effects of concentrated ambient ultrafine particulate matter on hallmarks of Alzheimerâ€ the 3xTgAD mouse model. NeuroToxicology, 2021, 84, 172-183.	™s disease in	3.0	15
273	Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease E Inhibition of Amyloid-peptide Aggregation. Mini-Reviews in Medicinal Chemistry, 2021, 21	specially on 1, 969-990.	2.4	6
274	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypothes Alzheimer's Disease, 2021, 82, 71-105.	es. Journal of	2.6	21
275	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug developmen Today, 2021, 26, 1330-1336.	t. Drug Discovery	6.4	3
276	Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Def Alzheimer's Disease (Mouse Model) Through Autophagy Induced by Activating Axl. In Journal of Molecular Sciences, 2021, 22, 5559.	iciency in ternational	4.1	22
277	Neuroprotective Natural Products for Alzheimer's Disease. Cells, 2021, 10, 1309.		4.1	90

#	Article	IF	CITATIONS
278	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. International Journal of Molecular Sciences, 2021, 22, 5549.	4.1	20
279	<sup>11</sup> C-PiB and <sup>124</sup> I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention. Journal of Nuclear Medicine, 2022, 63, 302-309.	5.0	19
280	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
281	Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. Transfusion and Apheresis Science, 2021, 60, 103164.	1.0	12
282	BACE1 controls synaptic function through modulating release of synaptic vesicles. Molecular Psychiatry, 2021, 26, 6394-6410.	7.9	20
283	Lifelong chronic psychosocial stress induces a proteomic signature of Alzheimer's disease in wildtype mice. European Journal of Neuroscience, 2022, 55, 2971-2985.	2.6	6
284	Amyloid β and Amyloid Precursor Protein Synergistically Suppress Large-Conductance Calcium-Activated Potassium Channel in Cortical Neurons. Frontiers in Aging Neuroscience, 2021, 13, 660319.	3.4	8
285	Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136.	3.3	33
286	An Overview of β-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. Current Medicinal Chemistry, 2022, 29, 114-135.	2.4	4
287	Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 219, 113441.	5.5	20
288	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	10.8	43
289	AÎα and AÎβ peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo. Alzheimer's Research and Therapy, 2021, 13, 125.	6.2	7
290	The Geriatrician, the Primary Care Physician, Aducanumab and the FDA Decision: From Frustration to New Hope. Journal of Nutrition, Health and Aging, 2021, 25, 821-823.	3.3	8
291	Post-translational modifications: Regulators of neurodegenerative proteinopathies. Ageing Research Reviews, 2021, 68, 101336.	10.9	45
292	BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory. Scientific Reports, 2021, 11, 15084.	3.3	3
293	Defective Autophagy and Mitophagy in Alzheimer's Disease: Mechanisms and Translational Implications. Molecular Neurobiology, 2021, 58, 5289-5302.	4.0	17
294	Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 8208.	4.1	62
295	On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. Clinical Trials, 2021, 18, 714-723.	1.6	3

#	Article	IF	CITATIONS
296	Novel bioengineered MBenes for the treatment of Alzheimer's disease: An in-Sillico study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12268-12276.	3.5	4
297	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	2.0	11
298	Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design. Current Drug Targets, 2022, 23, 266-285.	2.1	11
299	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	2.4	8
300	Casein Kinase 2 dependent phosphorylation of elF4B regulates BACE1 expression in Alzheimer's disease. Cell Death and Disease, 2021, 12, 769.	6.3	8
301	Soluble Amyloid-β Consumption in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415.	2.6	31
302	Combined association of cognitive impairment and poor oral health on mortality risk in older adults: Results from the NHANES with 15 years of followâ€up. Journal of Periodontology, 2022, 93, 888-900.	3.4	13
303	Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. Scientific Reports, 2021, 11, 17600.	3.3	11
304	Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-Brain Barrier in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 428-442.	1.4	19
305	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. Current Alzheimer Research, 2021, 18, 283-297.	1.4	3
306	Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review. Experimental Neurology, 2021, 343, 113743.	4.1	7
307	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. JAMA Network Open, 2021, 4, e2124124.	5.9	30
308	Discovery of Extremely Selective Fused Pyridine-Derived β-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. Journal of Medicinal Chemistry, 2021, 64, 14165-14174.	6.4	4
309	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	10.1	65
310	Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2020, 1299, 195-212.	1.6	15
311	Stress and Alzheimer's disease: A senescence link?. Neuroscience and Biobehavioral Reviews, 2020, 115, 285-298.	6.1	29
318	The Neuropsychiatric Inventory: Development and Applications. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 73-84.	2.3	83
319	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	1.7	42

#	Article	IF	CITATIONS
320	Alzheimer's disease as a multistage process: an analysis from a population-based cohort study. Aging, 2019, 11, 1163-1176.	3.1	12
321	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease. Current Pharmaceutical Design, 2020, 26, 509-516.	1.9	9
322	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	1.9	12
323	Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 418-452.	1.4	88
324	Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 85-93.	1.4	49
325	Amyloid-Negative Dementia in the Elderly is Associated with High Accumulation of Tau in the Temporal Lobes. Open Biomedical Engineering Journal, 2019, 13, 55-66.	0.5	1
326	Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. Annals of Integrative Molecular Medicine, 2019, 2, 90-114.	0.0	14
327	Alzheimer's Disease Prevention and Treatment: Case for Optimism. Annals of Integrative Molecular Medicine, 2019, 2, 0115-0130.	0.0	5
328	Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering. Neural Regeneration Research, 2020, 15, 783.	3.0	25
329	Intranasal Administration of Conditioned Medium from Cultured Mesenchymal Stem Cells Improves Cognitive Impairment in Olfactory Bulbectomized Mice. Advances in Alzheimer's Disease, 2020, 09, 47-56.	0.9	1
330	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. ELife, 2019, 8,	6.0	83
332	Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	10.9	131
333	Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease. Journal of Medicinal Chemistry, 2021, 64, 15262-15279.	6.4	14
334	Structure–activity relationship study of hydroxyethylamine isostere and P1′ site structure of peptide mimetic BACE1 inhibitors. Bioorganic and Medicinal Chemistry, 2021, 50, 116459.	3.0	2
335	Amyloid peptide exerts a rapid induction of Dicer1 protein in neuron via reducing phosphorylation. Neurochemistry International, 2021, 151, 105210.	3.8	1
336	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 226, 113889.	5.5	13
338	Alzheimer's Disease - Clinical Trials. Materials and Methods, 0, 8, .	0.0	0
339	Neuro-inflammation dans les maladies neurologiques. RÃ1e des probiotiques. Phytotherapie, 2018, 16, 326-335.	0.1	0

#	Article	IF	CITATIONS
340	Geriatrics update 2018: Challenges in mental health, mobility, and postdischarge care. Cleveland Clinic Journal of Medicine, 2018, 85, 953-958.	1.3	1
341	A Novel Cell-based β-secretase Enzymatic Assay for Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 128-134.	1.4	0
342	News from Mars: Two-Tier Paradox, Intracellular PCR, Chimeric Junction Shift, Dark Matter mRNA and Other Remarkable Features of Mammalian RNA-Dependent mRNA Amplification. Implications for Alzheimer's Disease, RNA-Based Vaccines and mRNA Therapeutics. Annals of Integrative Molecular Medicine, 2019, 2, 0131-0173.	0.0	4
343	Safety and tolerability of GRF6019 in mildâ€toâ€moderate Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12115.	3.7	6
348	RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model. Acta Neurobiologiae Experimentalis, 2020, 80, 225-244.	0.7	13
350	Comparative functional genomic analysis of Alzheimer's affected and naturally aging brains. PeerJ, 2020, 8, e8682.	2.0	3
351	Facteurs de risque de la maladie d'Alzheimer et des maladies apparentéesÂ: approche parcours de vie. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 217-223.	0.0	1
352	Applying C. elegans to the Industrial Drug Discovery Process to Slow Aging. Frontiers in Aging, 2021, 2,	2.6	3
353	Neuropsychological, neuropsychiatric, and qualityâ€ofâ€life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. Alzheimer's and Dementia, 2022, 18, 1314-1324.	0.8	17
354	Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells. Nature Cancer, 2021, 2, 1136-1151.	13.2	41
356	Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128463.	2.2	0
357	Inhibition of BACE1 and amyloid β aggregation by polyketide from <i>Streptomyces</i> sp Chemical Biology and Drug Design, 2022, 99, 264-276.	3.2	0
358	Nutrition senolytics - illusion or reality for cognitive ageing?. Current Opinion in Clinical Nutrition and Metabolic Care, 2021, Publish Ahead of Print, 7-28.	2.5	2
359	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 457-472.	2.6	6
360	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	1
361	Handling Intercurrent Events Through Hypothetical Strategy in Delayed-Start Designs. Statistics in Biopharmaceutical Research, 0, , 1-19.	0.8	0
362	Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure. Bioorganic and Medicinal Chemistry, 2021, 52, 116517.	3.0	1
363	BACE1: A Key Regulator in Alzheimer's Disease Progression and Current Development of its Inhibitors. Current Neuropharmacology, 2022, 20, 1174-1193.	2.9	12

# 365	ARTICLE Sulforaphane ameliorates amyloid-β-induced inflammatory injury by suppressing the PARP1/SIRT1 pathway in retinal pigment epithelial cells. Bioengineered, 2022, 13, 7079-7089.	IF 3.2	Citations 8
366	Mechanistic and therapeutic implications of EphAâ€4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5532-5546.	2.6	8
367	Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease. , 2022, 2, .		3
368	The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimer's disease. Reviews in the Neurosciences, 2022, 33, 515-529.	2.9	7
369	Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training. Metabolic Brain Disease, 2022, 37, 559-580.	2.9	4
370	Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species. Journal of Alzheimer's Disease Reports, 2022, 6, 1-15.	2.2	4
371	Role of prolineâ€rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5442-5452.	2.6	2
372	A short peptide from sAPPα binding to BACE1-APP action site rescues Alzheimer-like pathology. Neuroscience Letters, 2022, 770, 136397.	2.1	1
373	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5516-5531.	2.6	13
374	Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches. Neuron, 2022, 110, 366-393.	8.1	45
375	Physiology and pharmacology of amyloid precursor protein. , 2022, 235, 108122.		33
376	BACE1: More than just a βâ€secretase. Obesity Reviews, 2022, 23, e13430.	6.5	32
377	Hope or hype? Aducanumab as a magic bullet for Alzheimer's disease. BIO Integration, 2022, 3, .	1.3	3
379	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		Ο
380	Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science. Alzheimer's and Dementia, 2022, , .	0.8	1
381	Effects of microRNA-298 on APP and BACE1 translation differ according to cell type and 3′-UTR variation. Scientific Reports, 2022, 12, 3074.	3.3	8
383	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	46.4	273
384	Neurodegenerative Diseases: The Value of Early Predictive End Points. Clinical Pharmacology and Therapeutics, 2022, 111, 835-839.	4.7	3

#	Article	IF	CITATIONS
386	Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease. Frontiers in Neuroscience, 2022, 16, 854992.	2.8	12
387	Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. Journal of Alzheimer's Disease, 2022, 87, 83-100.	2.6	56
388	KIBRA regulates amyloid β metabolism by controlling extracellular vesicles secretion. EBioMedicine, 2022, 78, 103980.	6.1	1
389	A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials. AAPS Journal, 2022, 24, 53.	4.4	4
390	An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat. AAPS Journal, 2022, 24, 52.	4.4	2
391	Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy. Journal of Controlled Release, 2022, 345, 38-61.	9.9	11
392	Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact. Journal of Clinical Medicine, 2021, 10, 5986.	2.4	1
393	The β-Secretase Substrate Seizure 6–Like Protein (SEZ6L) Controls Motor Functions in Mice. Molecular Neurobiology, 2022, 59, 1183-1198.	4.0	3
394	Association of CSF Aβ <sub>38</sub> Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.1	16
396	PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimer's Disease: A Data Mining and Bioinformatics Study. International Journal of Molecular Sciences, 2022, 23, 4568.	4.1	4
410	Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	2
411	Shared pathophysiology: Understanding stroke and Alzheimer's disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	1.4	9
412	The future of stem cell therapies of Alzheimer's disease. Ageing Research Reviews, 2022, 80, 101655.	10.9	5
414	Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics. Experimental Neurobiology, 2022, 31, 65-88.	1.6	21
415	Mouse Models of Alzheimerâ $\in$ Ms Disease. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	50
416	Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases. Current Medicinal Chemistry, 2023, 30, 2357-2395.	2.4	12
417	Prophylactic evaluation of verubecestat on disease―and symptomâ€modifying effects in 5XFAD mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	5
418	The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer's Disease and for Its Potential Cure at Symptomatic Stages. Journal of Alzheimer's Disease Reports, 2022, 6, 369-399.	2.2	6

#	Article	IF	CITATIONS
419	Antiamyloid therapy of Alzheimer's disease: origins, current state and prospects of development. Neurology Bulletin, 2022, LIV, 56-68.	0.1	0
420	Pharmacotherapy for Alzheimer's disease: what's new on the horizon?. Expert Opinion on Pharmacotherapy, 0, , 1-19.	1.8	1
421	Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice. Neurochemistry International, 2022, 159, 105385.	3.8	8
422	Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1399-1429.	2.5	15
423	Exploratory analyses of clinical trial data used for health technology assessments: a retrospective evaluation. BMJ Open, 2022, 12, e058146.	1.9	0
424	Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease. Molecular Imaging and Biology, 2022, 24, 862-873.	2.6	2
425	Treatment of Alzheimer's disease by promoting the aggregation of small β-amyloid peptides. Scientia Sinica Vitae, 2022, 52, 1184-1191.	0.3	2
426	Diagnostic and therapeutic potential of protease inhibition. Molecular Aspects of Medicine, 2022, 88, 101144.	6.4	7
427	Analysis on the Pathogenesis and Nursing of Alzheimer's Disease. SHS Web of Conferences, 2022, 144, 01013.	0.2	1
428	Patents and applications of N-sulfonated N-heterocycles. , 2022, , 447-496.		2
429	Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	6
430	Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients. Brain Communications, 2022, 4, .	3.3	1
431	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
432	Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-β Load and Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-8.	2.6	3
433	Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta. Brain Communications, 2022, 4, .	3.3	5
434	A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora. Journal of Alzheimer's Disease, 2022, , 1-13.	2.6	2
435	Experimental evidence for temporal uncoupling of brain $\hat{A^2}$ deposition and neurodegenerative sequelae. Nature Communications, 2022, 13, .	12.8	6
436	Physiological Roles of β-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. Neuroscience Bulletin, 2023, 39, 1289-1308.	2.9	13

#	Article	IF	CITATIONS
437	Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer's Disease Clinical Trials. Journal of Alzheimer's Disease, 2023, 91, 531-535.	2.6	3
438	The Strategies for Treating "Alzheimer's Diseaseâ€: Insulin Signaling May Be a Feasible Target. Current Issues in Molecular Biology, 2022, 44, 6172-6188.	2.4	5
439	BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?. Molecules, 2022, 27, 8823.	3.8	12
440	Role of monomeric amyloid-Î <sup>2</sup> in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacological Research, 2023, 187, 106631.	7.1	22
441	Experimental approaches for altering the expression of Abetaâ€degrading enzymes. Journal of Neurochemistry, 2023, 164, 725-763.	3.9	4
442	Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors. Journal of Biomolecular Structure and Dynamics, 2023, 41, 10900-10908.	3.5	1
443	Neuronal deletion of nSMase2 reduces the production of AÎ <sup>2</sup> and directly protects neurons. Neurobiology of Disease, 2023, 177, 105987.	4.4	0
444	Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer's: A Review. Current Topics in Medicinal Chemistry, 2023, 23, 77-97.	2.1	3
445	Advances in Alzheimer's disease's pharmacological treatment. Frontiers in Pharmacology, 0, 14, .	3.5	10
446	The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept. Journal of Alzheimer's Disease Reports, 2023, 7, 21-35.	2.2	4
447	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. Neuropharmacology, 2023, 229, 109478.	4.1	10
448	Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies. Ageing Research Reviews, 2023, 87, 101910.	10.9	9
449	Photoinduced Vicinal 1,2-Difunctionalization of Olefins for the Synthesis of Alkyl Sulfonamides. Organic Letters, 2023, 25, 1014-1019.	4.6	9
450	Mechanisms of amyloid-β34 generation indicate a pivotal role for BACE1 in amyloid homeostasis. Scientific Reports, 2023, 13, .	3.3	1
451	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.8	6
452	Disease-modifying vs symptomatic treatments: Splitting over lumping. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.8	5
453	The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130. Molecular Neurodegeneration, 2023, 18, .	10.8	4
454	Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2023, 92, 1001-1013.	2.6	0

#	Article	IF	CITATIONS
455	The effects of microglia-associated neuroinflammation on Alzheimer's disease. Frontiers in Immunology, 0, 14, .	4.8	20
456	The past and present of therapeutic strategy for Alzheimer's diseases: potential for stem cell therapy. Experimental Animals, 2023, 72, 285-293.	1.1	2
457	The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	14
458	Poor Translatability of Biomedical Research Using Animals — A Narrative Review. ATLA Alternatives To Laboratory Animals, 2023, 51, 102-135.	1.0	14
459	A comprehensive characterization of hippocampal feature ensemble serves as individualized brain signature for Alzheimer's disease: deep learning analysis in 3238 participants worldwide. European Radiology, 0, , .	4.5	2
460	Lecanamab Ushers in a New Era of Antiâ€Amyloid Therapy for Alzheimer's Disease. Annals of Neurology, 2023, 93, 877-880.	5.3	3
461	Accelerated Brain Volume Loss Caused by Antiâ $€``^î^2$ -Amyloid Drugs. Neurology, 2023, 100, .	1,1	53
462	New Insights into Alzheimer's Disease: Novel Pathogenesis, Drug Target and Delivery. Pharmaceutics, 2023, 15, 1133.	4.5	2
463	Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer's model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form. Alzheimer's Research and Therapy, 2023, 15, .	6.2	4
464	Vector enabled CRISPR gene editing – A revolutionary strategy for targeting the diversity of brain pathologies. Coordination Chemistry Reviews, 2023, 487, 215172.	18.8	0
465	Women and Alzheimer's disease. , 2023, , 273-305.		0
467	Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease. CNS Neuroscience and Therapeutics, 2023, 29, 2060-2073.	3.9	3
468	Repetitive transcranial magnetic stimulation may be superior to drug therapy in the treatment of Alzheimer's disease: A systematic review and Bayesian network metaâ€analysis. CNS Neuroscience and Therapeutics, 0, , .	3.9	1
469	Alzheimer Hastalığı ve Anti-Alzheimer Etkili Bileşiklerin Yapılarının Araştırılması. Hacettepe U Journal of the Faculty of Pharmacy, 0, , .	niversity 0.0	1
470	Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care. Neurology, 2023, 101, 610-620.	1.1	4
471	BACE-1 Inhibitors Targeting Alzheimer's Disease. Current Alzheimer Research, 2023, 20, 131-148.	1.4	2
472	Mapping new pharmacological interventions for cognitive function in Alzheimer's disease: a systematic review of randomized clinical trials. Frontiers in Pharmacology, 0, 14, .	3.5	1
473	Iron homeostasis imbalance and ferroptosis in brain diseases. MedComm, 2023, 4, .	7.2	8

#	Article	IF	CITATIONS
474	Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias. Neurotherapeutics, 2023, 20, 955-974.	4.4	2
475	An optimistic approach to nanotechnology in Alzheimer's disease management: An overview. Journal of Drug Delivery Science and Technology, 2023, 86, 104722.	3.0	1
476	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 2023, , 1-42.		0
478	Anti-amyloid: An antibody to cure Alzheimer's or an attitude. IScience, 2023, 26, 107461.	4.1	5
479	Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloidâ€Î² Cascade: Pros and Cons of Chemical and Biological Modalities. ChemBioChem, 2023, 24, .	2.6	0
480	A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation. Journal of Experimental Medicine, 2023, 220, .	8.5	5
481	The Amyloid Cascade Hypothesis 2.0 for Alzheimer's Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy. International Journal of Molecular Sciences, 2023, 24, 12246.	4.1	7
483	Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer's disease mutations. Brain, 2023, 146, 4903-4915.	7.6	4
484	Principles of Design of Clinical Trials for Prevention and Treatment of Alzheimer's Disease and Aging-Associated Cognitive Decline in the ACH2.0 Perspective: Potential Outcomes, Challenges, and Solutions. Journal of Alzheimer's Disease Reports, 2023, 7, 921-955.	2.2	2
485	Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet. Neurology, 2023, 101, .	1.1	8
486	Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences, 2023, 24, 13900.	4.1	3
487	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	30.7	20
488	Advances in the discovery of heterocyclic-based drugs against Alzheimer's disease. Expert Opinion on Drug Discovery, 2023, 18, 1413-1428.	5.0	0
489	Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis#. Current Alzheimer Research, 2023, 20, 440-452.	1.4	0
490	The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
491	The amyloid-β peptide: Guilty as charged?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 166945.	3.8	0
492	Recent advancement in therapeutic strategies for Alzheimer's disease: Insights from clinical trials. Ageing Research Reviews, 2023, 92, 102113.	10.9	2
493	Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease. Metabolic Brain Disease, 0, , .	2.9	0

#	Article	IF	CITATIONS
494	Design, synthesis, and biological evaluation of novel capsaicin-tacrine hybrids as multi-target agents for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2024, 143, 107026.	4.1	0
495	Modern approaches to pharmacotherapy of Alzheimer's disease. , 2023, 3, 31-40.		0
496	Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues. Expert Review of Neurotherapeutics, 2023, 23, 1113-1129.	2.8	1
497	Attenuated memory impairment and neuroinflammation in Alzheimer's disease by aucubin via the inhibition of ERK-FOS axis. International Immunopharmacology, 2024, 126, 111312.	3.8	0
498	Discovery of a Small-Molecule Modulator of the Autophagy-Lysosome Pathway That Targets Lamin A/C and LAMP1, Induces Autophagic Flux, and Affects Lysosome Positioning in Neurons. ACS Chemical Neuroscience, 0, , .	3.5	0
499	Asociación entre enfermedad periodontal y enfermedad de Alzheimer. Revista Bionatura, 2023, 8, 1-16.	0.4	0
500	Rational Development of a Small-Molecule Activator of CK1γ2 That Decreases C99 and Beta-Amyloid Levels. ACS Chemical Biology, 0, , .	3.4	0
501	Next Generation Therapeutic Strategy for Treatment and Prevention of Alzheimer's Disease and Aging-Associated Cognitive Decline: Transient, Once-in-a-Lifetime-Only Depletion of Intraneuronal Al <sup>2</sup> (iAl <sup>2</sup> ) by Its Targeted Degradation via Augmentation of Intra-iAl <sup>2</sup> -Cleaving Activities of BACE1 and/or BACE2. International Iournal of Molecular Sciences, 2023, 24, 17586.	4.1	2
502	Association Between β-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia. Neurology, 2024, 102, .	1.1	0
503	Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach. International Journal of Molecular Sciences, 2024, 25, 259.	4.1	0
504	Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments. Bioengineering, 2024, 11, 45.	3.5	0
505	Symptoms and conventional treatments of Alzheimer's disease. , 2024, , 213-234.		1
506	Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer's disease mouse model by regulating the expression of APP secretases. Alzheimer's Research and Therapy, 2024, 16, .	6.2	1
507	Passive immunotherapy for Alzheimer's disease. Ageing Research Reviews, 2024, 94, 102192.	10.9	0
508	Lactiplantibacillus plantarum X7022 Plays Roles on Aging Mice with Memory Impairment Induced by D-Galactose Through Restoring Neuronal Damage, Relieving Inflammation and Oxidative Stress. Probiotics and Antimicrobial Proteins, 0, , .	3.9	0
509	Baricitinib and tofacitinib offâ€ŧarget profile, with a focus on Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2024, 10, .	3.7	0
510	Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets. BioScience Trends, 2024, 18, 49-65.	3.4	0
511	On the Inadequacy of the Current Transgenic Animal Models of Alzheimer's Disease: The Path Forward. International Journal of Molecular Sciences, 2024, 25, 2981.	4.1	0

# ARTICLE

IF CITATIONS